AKTX Akari Therapeutics

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Akari Therapeutics, Plc - AKTX

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Akari Therapeutics, Plc securities (NASDAQ: AKTX) from March 30, 2017 through May 11, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Akari Therapeutics investors under the federal securities laws.

To join the Akari Therapeutics class action, go to http://www.rosenlegal.com/cases-1127.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Akari Therapeutics’s CEO, and possibly other executives, were involved in publishing false information about Akari Therapeutics, including false information about the Phase 2 PNH trial of Coversin; (2) Akari Therapeutics lacked adequate checks and protections to prevent such behavior; and (3) as a result, defendants’ statements about Akari Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1127.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

EN
15/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akari Therapeutics

 PRESS RELEASE

AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Rema...

NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX). Investor losses must relate to purchases of the Company’s securities between March 30, 2017 and May 11, 2017. This action is pending in the United States District Court for the Southern ...

 PRESS RELEASE

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...

 PRESS RELEASE

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...

 PRESS RELEASE

AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney Gene...

NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX), if they purchased the Company’s securities between March 30, 2017, and May 11, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York. ...

 PRESS RELEASE

Akari Therapeutics Announces Resignation of CEO

NEW YORK & LONDON--(BUSINESS WIRE)-- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced the resignation of Gur Roshwalb, the Company’s Chief Executive Officer, and correction to fifth patient data in the Company’s press release issued on April 24, 2017 (the “Release”). As previously reported by the Company, its Board of Directors established an ad hoc special committee of the Board to review the involvement, if any, of Company personnel with the report issued by ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch